Financial Performance - Product revenues for Q3 2025 reached $209.4 million, a 31.5% increase from $159.3 million in Q3 2024[19] - Gross profit for the nine months ended September 30, 2025, was $334.9 million, compared to $279.1 million for the same period in 2024, reflecting a 19.9% increase[19] - Net income for Q3 2025 was $31.5 million, significantly up from $9.3 million in Q3 2024, representing a 237.5% increase[19] - The company reported a comprehensive income of $31.5 million for Q3 2025, compared to $9.9 million in Q3 2024, reflecting a 217.4% increase[22] - Net income for the three months ended September 30, 2025, was $31,507, compared to $9,335 for the same period in 2024, representing a year-over-year increase of 237%[70] - The effective tax rate for the three months ended September 30, 2025, was 27.5%, a decrease from 40.1% in the same period of 2024[173] Assets and Liabilities - Total current assets increased to $613.9 million as of September 30, 2025, compared to $482.3 million at the end of 2024, marking a 27.3% growth[16] - Total liabilities decreased to $1.33 billion as of September 30, 2025, down from $1.43 billion at the end of 2024, a reduction of 7.8%[16] - Cash and cash equivalents rose to $150.1 million as of September 30, 2025, compared to $70.6 million at the end of 2024, an increase of 112.5%[16] - Total assets measured at fair value as of September 30, 2025, amounted to $173,154 million, an increase from $130,344 million as of December 31, 2024[74] - The fair value of the Company's 2.875% convertible senior notes due in 2029 was $286,491 million with a net carrying value of $237,950 million as of September 30, 2025[78] Revenue Recognition and Accounting - The Company recognized revenue when a customer obtains control of promised goods, typically upon delivery, with payment received 30 to 90 days after[43] - The Company bases its estimates of variable consideration on historical data, including timing of rebates and returns, pricing adjustments, and quantity of products expected to be rebated or returned[45] - Provisions for product returns are based on product-level return rates and are estimated at the time of revenue recognition[47] - The Company provides an 18-month return window for customers, starting six months prior to expiration and ending twelve months after[48] - The Company disaggregates revenue from contracts with customers by product to reflect how economic factors affect revenue and cash flows[55] Acquisition and Intangible Assets - The Company closed its acquisition of Ironshore Therapeutics Inc. on September 3, 2024, acquiring the Jornay PM product, which has commercial approval in the U.S.[27] - The Ironshore Acquisition was completed on September 3, 2024, for a total consideration of approximately $306,104, which includes $276,888 in cash and $29,216 in deferred and contingent payments[62] - The fair value of acquired intangible assets from the Ironshore Acquisition was recorded at $635,000, amortized over a useful life of 7.7 years[65] - The total identifiable net assets acquired in the Ironshore Acquisition amounted to $294,036, with goodwill recorded at $12,068[64] Operating Expenses - Operating expenses for the nine months ended September 30, 2025, were $216.0 million, up from $147.3 million in the same period of 2024, a 46.7% increase[19] - Total commercial expenses for the three months ended September 30, 2025, were $36.93 million, up from $20.08 million in the same period of 2024, indicating an increase of 83.5%[177] - Selling, general and administrative expenses increased by $69.9 million to $217.2 million in the 2025 Period, primarily due to higher salaries and marketing expenses following the Ironshore Acquisition[210] - Salaries, wages, and benefits rose by $42.2 million, driven by additional headcount from the Ironshore Acquisition and executive transitions[210] - Sales and marketing expenses increased by $34.7 million to support the commercialization of Jornay PM post-Ironshore Acquisition[210] Stock and Shareholder Activities - The total shareholders' equity as of June 30, 2025, was $232.21 million, reflecting a net income of $31.51 million for the period[119] - The company repurchased shares under the Accelerated Share Repurchase agreement, resulting in a reduction of $25.01 million in treasury stock[119] - The company repurchased 2,704,830 shares at a weighted-average price of $31.43 per share, totaling $85,025 under the 2024-2025 Repurchase Program[127] - The 2025 Plan has 3,257,241 shares available for issuance as of September 30, 2025, with an aggregate of 1,600,000 shares authorized for issuance[121] - The company has not yet repurchased shares under the 2025-2026 Repurchase Program, leaving $150,000 available for share repurchases as of September 30, 2025[129] Legal Proceedings - The company is currently involved in multiple legal proceedings, including patent infringement lawsuits related to Xtampza ER and Nucynta, but is unable to estimate potential losses at this stage[146][150] - The company plans to vigorously defend against ongoing litigation, including the Merger Litigations related to the BDSI Acquisition, which allege violations of the Exchange Act[156][159] - The company has settled a patent infringement dispute with Aquestive Therapeutics for a one-time payment of $8,500, recognized as an expense in the consolidated statements of operations for the year ended December 31, 2023[155] - The company has received subpoenas related to opioid sales and marketing practices and is cooperating with investigations from several state Attorney General offices[151][152] Product Performance - Jornay PM generated $41,802 in revenue for the three months ended September 30, 2025, compared to $7,961 in the same period of 2024, reflecting a significant increase of 424%[56] - For the nine months ended September 30, 2025, product revenues were $575.1 million, a 27.9% increase from $449.5 million in the same period of 2024, driven by strong performance from Jornay PM and Nucynta Products[204] - Gross profit for the three months ended September 30, 2025, was $129.2 million, compared to $96.8 million in the same period of 2024, reflecting a gross margin improvement[189] - Jornay PM revenue increased by $33.8 million due to its acquisition from Ironshore Therapeutics in September 2024[191] - Nucynta Products revenue rose by $9.7 million, attributed to lower gross-to-net adjustments and higher gross prices, despite lower sales volume[192]

MADISON SQUARE GARDEN ENTERTAINMENT CORP. REPORTS FISCAL 2026 FIRST QUARTER RESULTS Results for the Three Months Ended September 30, 2025 and 2024: | | | | | Three Months Ended | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | September 30, | | | | Change | | | | $ millions | 2025 | | | 2024 | | $ | % | | Revenues | $ 158.3 | | $ | 138.7 $ | | 19.5 | 14 % | | Operating Loss | $ (29.7) $ | | | (18.5) $ | | (11.3) | (61)% | | (1) Adjusted Operating Income | $ | 7.1 | $ | 1.9 $ | | 5.2 | NM | Note: ...

Financial Performance - The net loss for the three months ended September 30, 2025, was $24,607,000, compared to a net loss of $2,631,000 for the period from September 19, 2024, through September 30, 2024[32]. - For the nine months ended September 30, 2025, the net loss was $61,545 thousand, compared to a net loss of $2,631 thousand for the same period in 2024[41]. - The net loss per share attributable to ordinary shareholders for the nine months ended September 30, 2025, was $7.89, compared to $3.60 for the period from September 19, 2024, through September 30, 2024[32]. - Crescent recorded a net loss of $24.6 million for the three months ended September 30, 2025, compared to a loss of $2.6 million for the period from September 19, 2024, through September 30, 2024[190]. - The net loss for the nine months ended September 30, 2025, was $61.5 million, compared to a loss of $2.6 million for the same period in 2024, representing an increase in loss of $58.9 million[202]. Assets and Liabilities - As of September 30, 2025, total assets increased to $138,269,000 from $35,617,000 as of December 31, 2024, representing a growth of 287%[27]. - Total current liabilities increased to $20,304,000 from $9,614,000, reflecting a rise of 111%[27]. - Shareholders' equity improved to $116,641,000 as of September 30, 2025, from a deficit of $15,479,000 as of December 31, 2024[27]. - The balance of accumulated deficit as of September 30, 2025, was $(79,412) thousand, reflecting the ongoing losses[41]. - Cash, cash equivalents, and restricted cash at the end of the period was $133,372 thousand, an increase of $98,606 thousand from the beginning of the period[41]. Cash Flow and Financing - The company reported a net cash used in operating activities of $44,792 thousand for the nine months ended September 30, 2025[41]. - Proceeds from Pre-Closing Financing amounted to $143,027 thousand, contributing to the net cash provided by financing activities of $144,124 thousand[41]. - The company raised approximately $142.3 million in net proceeds from Pre-Closing Financing in June 2025, contributing to its liquidity position[208]. - As of September 30, 2025, the company had cash and cash equivalents of $133.3 million, expected to fund operations for at least twelve months[60]. Research and Development - Research and development expenses for the three months ended September 30, 2025, were $20,347,000, up from $2,473,000 for the same period last year[32]. - Research and development expenses for the nine months ended September 30, 2025, totaled $43.1 million, a significant increase from $2.5 million for the same period in 2024, reflecting a change of $40.6 million[203]. - Crescent's research and development expenses included $5.7 million related to chemistry, manufacturing, and development costs for CR-001 in preparation for clinical trials[197]. - The company expects significant increases in research and development and general and administrative costs related to future clinical trials and commercialization efforts[60]. - The company has incurred significant external research and development costs, totaling $8.7 million for CR-001 and $6.7 million for CR-002 for the three months ended September 30, 2025[159]. Shareholder Equity and Stock Options - The company issued 20,000,000 shares of convertible preferred stock valued at $4,000 thousand during its inception[38]. - The total stockholders' equity (deficit) as of September 30, 2025, was $116,641 thousand[38]. - The 2025 Stock Incentive Plan has an initial share pool of 2,345,962 ordinary shares, with 1,955,408 shares available as of September 30, 2025[118]. - The aggregate intrinsic value of stock options as of September 30, 2025, was $14,815 thousand, with an outstanding balance of 4,094,237 options[122]. - For the nine months ended September 30, 2025, the total share-based compensation expense was $8.55 million, with $5.25 million attributed to general and administrative expenses and $3.30 million to research and development[129]. Merger and Acquisitions - The company completed a reverse recapitalization on June 13, 2025, merging with Pre-Merger Crescent, which is focused on developing therapies for solid tumors[49]. - The merger was accounted for as a reverse recapitalization, with Pre-Merger Crescent deemed the accounting acquirer[54]. - The Exchange Ratio for the merger was set at 0.1445 shares of GlycoMimetics common stock for each share of Pre-Merger Crescent common stock, reflecting a 1-for-100 reverse stock split[52]. - Following the merger with GlycoMimetics, the company raised approximately $200.0 million in gross proceeds through a subscription agreement with investors[173]. Future Outlook - The company plans to submit an Investigational New Drug application for CR-001 in Q4 2025, with initial clinical data anticipated in the second half of 2026[165]. - The company expects to continue incurring substantial losses for the foreseeable future, with profitability dependent on the successful development and commercialization of its product candidates[168]. - The company has not generated any revenue from product sales and relies on equity offerings and debt financings for operating activities[58]. - The company has not yet commercialized any products and does not expect to generate revenue from product sales for several years[208].

Financial Forecast and Usage - As of September 30, 2025, the company has forecasted diesel fuel usage of 21.4 million gallons, with 96.0% priced at an average of $2.74 per gallon[191] - The company maintains a senior secured asset-based revolving credit facility with a borrowing capacity of up to $225.0 million, with no cash borrowings outstanding as of September 30, 2025[192] - Investments in trading securities amounted to $83.6 million as of September 30, 2025, compared to $43.1 million as of December 31, 2024[194] Risk Management - The company has exposure to commodity price risk for coal sales, managed through coal supply agreements[189] - The company does not have material exposure to foreign currency exchange-rate risks, as transactions are denominated in U.S. dollars[195] Corporate Developments - The company completed a merger with ANR, Inc. and Alpha Natural Resources Holdings, Inc. on November 9, 2018, enhancing its market position[21] Operational Metrics - The company’s coal reserves are defined as the economically mineable part of a measured coal resource, which includes allowances for losses during extraction[16] - The company’s operating margin is calculated as coal revenues less the cost of coal sales, reflecting operational efficiency[23] - The company’s productivity is measured in clean metric tons of coal produced per underground man hour worked, as published by MSHA[24] Environmental Responsibility - The company is focused on reclamation processes to restore land and the environment post-mining, which is closely regulated by state and federal law[26]

Regulatory and Operational Challenges - The company is undergoing a public investigation related to alleged dumping of medical cannabis imports into Israel, which may impact operations and costs associated with anti-dumping duties [124]. - The company is navigating regulatory challenges related to cannabis legalization in various jurisdictions, which may impact market opportunities [126]. Cost Management and Operational Efficiency - The company has announced cost-cutting measures, including winding down operations at the Winnipeg facility, which is expected to yield significant cost savings [124]. - The company is realigning its operations to improve efficiency and reduce costs, with ongoing assessments of employee turnover and operational metrics [126]. - The company is exploring joint ventures and strategic alliances to improve revenue and operational efficiencies [124]. - The company is committed to expanding its Stayner, Ontario facility to enhance production capabilities [126]. Financial Performance - For the three months ended September 30, 2025, consolidated net revenue was $36.3 million, a 6% increase from $34.3 million in the same period of 2024 [138]. - For the nine months ended September 30, 2025, consolidated net revenue reached $102.1 million, representing a 17% increase from $87.3 million in the same period of 2024 [138]. - Gross profit for the three months ended September 30, 2025, was $18.3 million, a significant increase of 408% from $3.6 million in the same period of 2024 [141]. - Gross profit for the nine months ended September 30, 2025, was $46.6 million, an increase of 224% from $14.4 million in the same period of 2024 [141]. - Consolidated cost of sales for the three months ended September 30, 2025, was $17.5 million, a decrease of 42% from $30.3 million in the same period of 2024 [139]. - Total operating expenses for the three months ended September 30, 2025, were $18.8 million, a 49% decrease from $37.3 million in the same period of 2024 [142]. - The improvement in net income and Adjusted EBITDA was primarily due to higher gross profit and lower operating expenses, particularly a decline in general and administrative costs [174]. Income and Adjusted Metrics - For the three months ended September 30, 2025, net income was $28.3 million, an increase from $7.3 million for the same period in 2024 [164]. - For the nine months ended September 30, 2025, net loss was $2.4 million, an improvement from a net loss of $3.9 million for the same period in 2024 [164]. - Adjusted EBITDA for the three months ended September 30, 2025, was $5.7 million, representing an improvement of $11.7 million from the same period in 2024 [174]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $9.7 million, an improvement of $37.4 million from the same period in 2024 [174]. Cash Flow and Investments - Cash and cash equivalents as of September 30, 2025, were $784.2 million, a 9% decrease from $858.8 million as of December 31, 2024 [180]. - The company generated $14.0 million of cash from operating activities during the nine months ended September 30, 2025, compared to $11.1 million in the same period in 2024, representing an increase of $2.9 million [188]. - Cash used in investing activities during the nine months ended September 30, 2025, was $79.3 million, a change of $259.5 million compared to cash provided by investing activities in the same period in 2024 [189]. - Cash used in financing activities was $12.5 million during the nine months ended September 30, 2025, compared to $0.9 million in the same period in 2024, representing an increase of $11.6 million [190]. - The company authorized a share repurchase program of up to $50.0 million, with 917,862 shares repurchased in the three months ended September 30, 2025 [191].

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs - $30 Million Registered Direct Of ering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dementia with Lewy Bodies Ongoing - Purchase, NY – November 6, 2025 – Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical- stage company devel ...

Production and Operations - ConocoPhillips reported third-quarter 2025 production of 2,399 MBOED, an increase of 482 MBOED or 25% from the same period a year ago[151]. - Total production for the nine-month period of 2025 was 2,393 MBOED, an increase of 472 MBOED or 25% from the same period a year ago[170]. - Third-quarter 2025 production increased by 83 MBOED or 4% year-over-year, while nine-month production also rose by 92 MBOED or 4%[171]. - Average production in the Lower 48 increased by 381 MBOED in Q3 2025 and 402 MBOED in the nine-month period compared to the same periods in 2024[192]. - Average consolidated production increased by 56 MBOED and 46 MBOED in the three- and nine-month periods of 2025, respectively, due to assets acquired from Marathon Oil and new wells online in Norway and Libya[208]. - Average production increased by 40 MBOED and 24 MBOED in the three- and nine-month periods of 2025, respectively, due to new wells online and absence of prior-year planned turnaround activity[202]. Financial Performance - The company generated $5.9 billion in cash provided by operating activities in the third quarter of 2025[152]. - Sales and other operating revenues for Q3 2025 reached $15,031 million, up $1,990 million (15%) from Q3 2024; for the nine-month period, revenues increased to $45,552 million, up $5,043 million (12.5%) from the previous year[174]. - Net income for Q3 2025 was $1,726 million, down from $2,059 million in Q3 2024; for the nine-month period, net income was $6,546 million, compared to $6,939 million in the same period last year[179]. - Revenues and other income for the nine months ended September 30, 2025, were $29.29 billion, with a net income of $6.55 billion[248]. Dividends and Share Repurchases - ConocoPhillips raised its ordinary dividend by 8% to $0.84 per share in November 2025[151]. - The company paid ordinary dividends of $2.34 per share in the first nine months of 2025, compared to $1.74 per share in the same period of 2024, representing a 34.5% increase[240]. - The company repurchased 42.2 million shares for a cost of $4.0 billion in the nine months ended September 30, 2025, totaling 474.8 million shares and $38.3 billion since the program's inception[241]. Capital Expenditures and Investments - Capital expenditures and investments for the first nine months of 2025 were $9.5 billion, with expected operating plan capital expenditures for 2025 between $12.3 billion and $12.6 billion[227]. - The company anticipates capital expenditures for 2025 to be between $12.3 billion and $12.6 billion, compared to $12.1 billion in 2024[244]. - Capital expenditures and investments for the first nine months of 2025 totaled $9.53 billion, compared to $8.80 billion in the same period of 2024, reflecting a 8.3% increase[243]. Asset Management - The company completed over $3 billion in asset dispositions in 2025 and is on track to meet its $5 billion target by year-end 2026[148]. - The company completed divestitures totaling approximately $2.6 billion, including the recent $1.3 billion sale of Anadarko Basin assets[194]. - Proceeds from asset sales were $1.6 billion in the first nine months of 2025, compared to $0.2 billion for the same period in 2024[229]. Liquidity and Debt - The company ended the third quarter of 2025 with cash, cash equivalents, restricted cash, and short-term investments totaling $6.6 billion[152]. - Total liquidity at September 30, 2025, was $11.8 billion, comprised of cash and cash equivalents of $5.3 billion, short-term investments of $1.0 billion, and available borrowing capacity of $5.5 billion[222]. - As of September 30, 2025, the company's debt balance was $23.5 billion, down from $24.3 billion at December 31, 2024[234]. - The company refinanced its revolving credit facility, maintaining a total principal amount of $5.5 billion, with an expiration extended to February 2030[233]. Segment Performance - The Lower 48 segment reported net income of $1,240 million in Q3 2025, slightly down from $1,241 million in Q3 2024; for the nine-month period, net income increased to $4,429 million from $3,881 million[189]. - Canada segment earnings rose to $188 million in Q3 2025 from $25 million in Q3 2024, and for the nine-month period, earnings increased to $593 million from $466 million[199]. - Europe, Middle East and North Africa segment reported sales and other operating revenues of $1,578 million and $4,918 million for the three- and nine-month periods of 2025, respectively, compared to $1,337 million and $4,090 million in 2024[203]. - Net income for the Europe, Middle East and North Africa segment was $327 million and $983 million for the three- and nine-month periods of 2025, respectively, up from $298 million and $853 million in 2024[205]. - Asia Pacific segment reported sales and other operating revenues of $515 million and $1,410 million for the three- and nine-month periods of 2025, respectively, compared to $478 million and $1,495 million in 2024[209]. - Net income for the Asia Pacific segment was $309 million and $950 million for the three- and nine-month periods of 2025, respectively, down from $455 million and $1,411 million in 2024[211]. Market Conditions and Risks - The average realized price for total production was $46.44 per BOE, a decrease of 14% compared to $54.18 per BOE in the third quarter of 2024[160]. - The average Brent crude oil price was $69.07 per barrel in the third quarter of 2025, a decrease of 14% from $80.18 per barrel in the same quarter of 2024[157]. - The company cautions that forward-looking statements are based on current expectations and may not guarantee future performance due to various risks and uncertainties[260]. - Potential impacts from volatile commodity prices could adversely affect operating results and lead to impairment charges on long-lived assets[260]. - The company faces risks related to global demand and supply changes in oil and gas, influenced by geopolitical events and health crises[260]. - There are concerns about liquidity that could impact the company's ability to repurchase shares and pay dividends[261]. - The company highlights risks associated with achieving expected reserve or production levels due to operational hazards and drilling risks[261]. - Legislative and regulatory changes addressing environmental concerns may impose significant operational or investment changes[261]. - The company acknowledges competition and consolidation in the oil and gas E&P industry, affecting access to supply and services[261]. - Challenges related to the acquisition of Marathon Oil may disrupt operations and hinder realization of anticipated cost savings[261]. - The company emphasizes the importance of reliable transportation for crude oil and natural gas, with potential disruptions posing risks[261]. - Market risks for the nine months ended September 30, 2025, remain consistent with previous disclosures in the 2024 Annual Report[262].

Remarks by Anil Singhal, NETSCOUT's President & Chief Executive Officer: "We delivered another solid quarter in Q2, driven by revenue growth from both our Cybersecurity and Service Assurance product lines as we continued to advance our strategic initiatives, including AI-driven product innovation. Our strong top and bottom-line performance also benefited from the acceleration of some orders originally anticipated in the second half of the fiscal year. NETSCOUT Reports Second Quarter Fiscal Year 2026 Financi ...

Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES R&D UPDATES FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 ...

Exhibit 99.1 Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance – Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 t ...